Paweł Syska

Dr. Paweł Syska

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2010 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
PSPaweł Syska
Paweł Syska
APAndrzej Przybylski
Andrzej Przybylski
LCLidia Chojnowska
Lidia Chojnowska
MLMichał Lewandowski
Michał Lewandowski
MSMaciej Sterliński
Maciej Sterliński
HSHanna Szwed
Hanna Szwed

4 October 2014 in Trials
Verified
Journal Article
Open access
PDF file
JCJan Ciszewski
Jan Ciszewski
AMAleksander Maciag
Aleksander Maciag
IKIlona Kowalik
Ilona Kowalik
PSPaweł Syska
Paweł Syska
MLMichal Lewandowski
Michal Lewandowski
MSMaciej Sterliński
Maciej Sterliński
The only subgroups of patients with heart failure and atrial fibrillation in which the efficacy of cardiac resynchronization therapy has been scientifically proven are patients with indications for right ventricular pacing and patients after atrioventricular junction ablation. However it is unlikely that atrioventricular junction ablation would be a standard procedure in the majority of the heart failure patients with cardiac resynchronization therapy and concomitant atrial fibrillation due to the irreversible character of the procedure and a spontaneous sinus rhythm resumption that occurs in about 10% of these patients. Pilot-CRAfT is the first randomized controlled trial evaluating the efficacy of a rhythm control strategy in atrial fibrillation patients with cardiac resynchronization therapy devices. The aim of this prospective, single center randomized controlled pilot study is to answer the question whether the patients with cardiac resynchronization therapy and permanent atrial fibrillation would benefit from a strategy to restore and maintain sinus rhythm (that is ‘rhythm control’ strategy) in comparison to rate control strategy. The study population consists of 60 patients with heart failure and concomitant long-standing persistent or permanent atrial fibrillation who underwent a cardiac resynchronization therapy device implantation at least 3 months before qualification. Study participants are randomly assigned to the rhythm control strategy (including electrical cardioversion and pharmacotherapy) or to the rate control group whose goal is to control ventricular rate. The follow-up time is 12 months. The primary endpoint is the ratio of effectively captured biventricular beats. The secondary endpoints include peak oxygen consumption, six-minute walk test distance, heart failure symptom escalation, reverse remodelling of the heart on echo and quality of life. NCT01850277 registered on 22 April 2013 (ClinicalTrails.gov)

12 May 2020 in Trials
Verified
Journal Article
Open access
PDF file
RDRafal Dabrowski
Rafal Dabrowski
PSPaweł Syska
Paweł Syska
JMJustyna Maczynska
Justyna Maczynska
MFMichal Miroslaw Farkowski
Michal Miroslaw Farkowski
SSStefan Sawicki
Stefan Sawicki
THTomasz Hryniewiecki
Tomasz Hryniewiecki
Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration. Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2–3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration. Other endpoints and safety outcomes analyses, due to expected lack of statistical power, are exploratory. Discussion: Current evidence supports renin–angiotensin–aldosterone system (RAAS) inhibition as an upstream therapy in AF management. Excess aldosterone secretion results in proarrhythmic effects. Among the RAAS inhibitors, only canrenone is administered intravenously. Canrenone additionally increases the plasma level of potassium, lowers blood pressure and reduces preload. It has been already used in primary and secondary hyperaldosteronism in the course of chronic liver dysfunction and in heart failure. Trial registration: ClinicalTrials.gov, NCT03536806. Registered on 25 May 2018.

27 June 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
MSMałgorzata Stępień-Wojno
Małgorzata Stępień-Wojno
JPJoanna Kinga Ponińska
Joanna Kinga Ponińska
EBElżbieta Katarzyna Biernacka
Elżbieta Katarzyna Biernacka
BFBogna Foss-Nieradko
Bogna Foss-Nieradko
TCTomasz Chwyczko
Tomasz Chwyczko
ZBZofia T. Bilińska
Zofia T. Bilińska
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is one of causes of sudden cardiac death in the young, especially in athletes. Diagnosis of CPVT may be difficult since all cardiological examinations performed at rest are usually normal, and exercise stress test-induced ventricular tachycardia is not commonly present. The identification of a pathogenic mutation in RYR2 or CASQ2 is diagnostic in CPVT. We report on a 20-year-old athlete who survived two sudden cardiac arrests during swimming. Moreover, he suffered repeated syncopal spells on exercise. The diagnosis was made only following genetic testing using a multi-gene panel, and the p.Arg420Gln RYR2 variant was identified. We present diagnostic and therapeutic issues in this young athlete with CPVT.

1 August 2007
Verified
Journal Article
Closed access
KGKatarzyna Gepner
Katarzyna Gepner
APAndrzej Przybylski
Andrzej Przybylski
AMAleksander Maciag
Aleksander Maciag
MSMaciej Sterliński
Maciej Sterliński
MLMichał Lewandowski
Michał Lewandowski
HSHanna Szwed
Hanna Szwed

30 April 2020 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
PSPaweł Syska
Paweł Syska